A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF)
- J. Mascarenhas
- , B. K. Marcellino
- , M. Lu
- , M. Kremyanskaya
- , F. Fabris
- , L. Sandy
- , M. Mehrotra
- , J. Houldsworth
- , V. Najfeld
- , S. El Jamal
- , B. Petersen
- , E. Moshier
- , R. Hoffman
- Cancer Clinical Investigation
- Graduate School of Biomedical Sciences
- Icahn School of Medicine at Mount Sinai
- Medicine
- Medicine - Hematology and Medical Oncology
- Mount Sinai Tisch Cancer Center
- Hematology-Oncology, Infectious Diseases, Palliative Care, Psychology, and Nutrition
- Institute for Translational Medicine and Pharmacology
- Mount Sinai Academy of Physician-Scientists
- Pathology, Molecular and Cell-Based Medicine
- Institute for Healthcare Delivery Science
- Black Family Stem Cell Institute
- Friedman Brain Institute
Research output: Contribution to journal › Article › peer-review
27
Scopus
citations